Eric Lefkofsky; The Battle Against Cancer can be Won Through Data Driven-Precision Medicine

Eric Lefkofsky is one of the most accomplished entrepreneurs who are committed to the welfare of others in the society. The businessman is an alumnus of the University of Michigan. He received a Juris Doctor from the institution. Over time, Eric lefkofsky has managed to establish his businesses in different sectors of the global economy. Together with his friend and business partner, Brad Keywell, Eric has developed over eight enterprises that dominate various industries in the US. Eric is also the co-founder and by far the most significant stakeholder of internet giant Groupon. The entrepreneur serves as the chairman of the company and only stepped down from the Chief Executive Officer position recently.

Eric has experienced the agony which families undergo when their loved one is diagnosed with cancer. He understands the emotional and financial drain that families have to deal with whenever their loved ones or someone close is affected by cancer. For a long time, Eric has always wanted to help advance research in the field of oncology. Recently, through a partnership with an institution of higher learning in Chicago, Eric Lefkofsky co-founded a biotechnology company called Tempus. The enterprise will be responsible for aggregating genomic and therapeutic data of cancer patients so that professionals can use the information for medical research. For a long time, the medical field of oncology has been operating with sufficient data on cancer patients. This reality has made the industry to remain behind in the hunt for effective and personalized treatments. Tempus also recognizes that doctors don’t have enough time to collect and structure in the right way so that it can be used for research.

Today, industries such as those for manufacturing and entertainment are relying on big data when coming up with a business solution. Tempus’ primary goal is to centralize relevant information on cancer patients and research in the field of oncology. The company is already reaching out samples of cancer patients to collect phenotypic, genomic and therapeutic data that can provide a clue on the effectiveness of various cancer therapies. If Tempus succeeds in its plans, the organization will usher a new era of data-enabled precision medicine. Such treatments will enable millions of patients to overcome the menace that cancer has become. Eric Lefkofsky believes that entrepreneurs should focus on solving a problem first before they can even think of making money.

http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale